B G Feagan

Summary

Affiliation: Robarts Research Institute
Country: Canada

Publications

  1. ncbi request reprint A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease
    William J Sandborn
    The Clinical Trials Task Force of the International Organization of Inflammatory Bowel Disease
    Gastroenterology 122:512-30. 2002
  2. ncbi request reprint The effects of infliximab maintenance therapy on health-related quality of life
    Brian G Feagan
    Robarts Research Institute, University of Western Ontario, London, Ontario, Canada
    Am J Gastroenterol 98:2232-8. 2003
  3. ncbi request reprint CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial
    B G Feagan
    University of Western Ontario, London, ON, Canada
    Aliment Pharmacol Ther 23:617-28. 2006
  4. ncbi request reprint The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients
    Brian G Feagan
    Robarts Research Institute, University of Western Ontario, London, Canada
    Am J Gastroenterol 102:794-802. 2007
  5. doi request reprint Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis
    Brian G Feagan
    Robarts Research Institute, University of Western Ontario, London, Ontario, Canada Electronic address
    Gastroenterology 146:110-118.e3. 2014
  6. ncbi request reprint Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? evidence from cochrane reviews
    Brian G Feagan
    Robarts Clinical Trials, Robarts Research Institute, London, Canada
    Inflamm Bowel Dis 19:2031-40. 2013
  7. doi request reprint Vedolizumab as induction and maintenance therapy for ulcerative colitis
    Brian G Feagan
    Robarts Clinical Trials, Robarts Research Institute, and Department of Medicine, University of Western Ontario, London, Canada
    N Engl J Med 369:699-710. 2013
  8. doi request reprint The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis
    Brian G Feagan
    Robarts Clinical Trials, Western University, London, Ontario, Canada
    Gastroenterology 145:149-157.e2. 2013
  9. doi request reprint Vedolizumab for Crohn's disease
    Mahmoud H Mosli
    University of Western Ontario, Robarts Research Institute, Department of Medicine, Robarts Clinical Trials, 100 Perth Dr, London, ON N6A 5K8, Canada
    Expert Opin Biol Ther 13:455-63. 2013
  10. doi request reprint Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
    Brian G Feagan
    Robarts Clinical Trials, Robarts Research Institute, London, Ontario, Canada
    Cochrane Database Syst Rev 10:CD000544. 2012

Detail Information

Publications56

  1. ncbi request reprint A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease
    William J Sandborn
    The Clinical Trials Task Force of the International Organization of Inflammatory Bowel Disease
    Gastroenterology 122:512-30. 2002
  2. ncbi request reprint The effects of infliximab maintenance therapy on health-related quality of life
    Brian G Feagan
    Robarts Research Institute, University of Western Ontario, London, Ontario, Canada
    Am J Gastroenterol 98:2232-8. 2003
    ..The ACCENT I study evaluated the long term effects of infliximab as maintenance therapy for patients with Crohn's disease. Health-related quality of life (HRQL) was also assessed in the trial...
  3. ncbi request reprint CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial
    B G Feagan
    University of Western Ontario, London, ON, Canada
    Aliment Pharmacol Ther 23:617-28. 2006
    ..More than 50% of patients with Crohn's disease become either steroid resistant or dependent. Accordingly, development of new treatments for steroid-dependent Crohn's disease is a research priority...
  4. ncbi request reprint The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients
    Brian G Feagan
    Robarts Research Institute, University of Western Ontario, London, Canada
    Am J Gastroenterol 102:794-802. 2007
    ..The impact of infliximab induction and maintenance therapy on health-related quality of life (HRQL) was evaluated in patients with ulcerative colitis (UC)...
  5. doi request reprint Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis
    Brian G Feagan
    Robarts Research Institute, University of Western Ontario, London, Ontario, Canada Electronic address
    Gastroenterology 146:110-118.e3. 2014
    ....
  6. ncbi request reprint Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? evidence from cochrane reviews
    Brian G Feagan
    Robarts Clinical Trials, Robarts Research Institute, London, Canada
    Inflamm Bowel Dis 19:2031-40. 2013
    ..The main objective of this review was to determine if there are any differences in efficacy or safety among the oral 5-ASA drugs...
  7. doi request reprint Vedolizumab as induction and maintenance therapy for ulcerative colitis
    Brian G Feagan
    Robarts Clinical Trials, Robarts Research Institute, and Department of Medicine, University of Western Ontario, London, Canada
    N Engl J Med 369:699-710. 2013
    ..Gut-selective blockade of lymphocyte trafficking by vedolizumab may constitute effective treatment for ulcerative colitis...
  8. doi request reprint The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis
    Brian G Feagan
    Robarts Clinical Trials, Western University, London, Ontario, Canada
    Gastroenterology 145:149-157.e2. 2013
    ..Interobserver differences in endoscopic assessments contribute to variations in rates of response to placebo in ulcerative colitis (UC) trials. We investigated whether centralized review of images could reduce these variations...
  9. doi request reprint Vedolizumab for Crohn's disease
    Mahmoud H Mosli
    University of Western Ontario, Robarts Research Institute, Department of Medicine, Robarts Clinical Trials, 100 Perth Dr, London, ON N6A 5K8, Canada
    Expert Opin Biol Ther 13:455-63. 2013
    ..As a result, patients with CD can develop serious complications that adversely affect quality of life. Consequently, new treatment options are needed...
  10. doi request reprint Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
    Brian G Feagan
    Robarts Clinical Trials, Robarts Research Institute, London, Ontario, Canada
    Cochrane Database Syst Rev 10:CD000544. 2012
    ..This updated review includes more recent studies and evaluates the effectiveness, dose-responsiveness, and safety of 5-ASA preparations used for maintenance of remission in quiescent ulcerative colitis...
  11. doi request reprint Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis
    Brian G Feagan
    Robarts Clinical Trials, Robarts Research Institute, London, Ontario, Canada
    Cochrane Database Syst Rev 10:CD000543. 2012
    ..This updated review includes more recent studies and evaluates the efficacy and safety of 5-ASA preparations used for the treatment of mild to moderately active ulcerative colitis...
  12. doi request reprint Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysis
    Brian G Feagan
    Robarts Clinical Trials, Robarts Research Institute, University of Western Ontario, London, Canada
    Inflamm Bowel Dis 18:1785-94. 2012
    ..The failure to demonstrate a superior rate of adherence to OD dosing may be due to the high rate of adherence observed in the clinical trials environment. Future research should assess the value of OD dosing in community settings...
  13. ncbi request reprint Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin
    Brian G Feagan
    Robarts Research Institute, London, ON N6A 5K8, Canada
    N Engl J Med 352:2499-507. 2005
    ..Selective blockade of interactions between leukocytes and vascular endothelium in the gut is a promising strategy for the treatment of inflammatory bowel diseases...
  14. ncbi request reprint Unemployment and disability in patients with moderately to severely active Crohn's disease
    Brian G Feagan
    University of Western Ontario, Robarts Research Institute, London, Ontario, Canada
    J Clin Gastroenterol 39:390-5. 2005
    ..Unemployment and disability rates in Crohn's disease patients from the ACCENT I trial were assessed. Factors associated with employment and disability status were explored...
  15. ncbi request reprint A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease
    B G Feagan
    The John P Robarts Research Institute, University of Western Ontario, London, ON, Canada
    Aliment Pharmacol Ther 21:373-84. 2005
    ..To evaluate CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for the treatment of corticosteroid-dependent Crohn's disease...
  16. doi request reprint Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials
    Brian G Feagan
    Robarts Clinical Trials, Robarts Research Institute, University of Western Ontario, 100 Perth Dr, London, ON, Canada N6A 5K8
    JAMA 299:1690-7. 2008
    ..Maintenance therapy for Crohn disease features the use of immunosuppressive drugs, which are associated with an increased risk of infection. Identification of safe and effective maintenance strategies is a priority...
  17. ncbi request reprint Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin
    Brian G Feagan
    Robarts Clinical Trials, Robarts Research Institute, London, Ontario, Canada
    Clin Gastroenterol Hepatol 6:1370-7. 2008
    ..This randomized, double-blind, controlled trial assessed the efficacy and safety of MLN0002, a monoclonal antibody targeting the alpha4beta7 integrin, in patients with active Crohn's disease...
  18. doi request reprint Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study
    Brian G Feagan
    Robarts Research Institute, The University of Western Ontario, London, Ontario, Canada
    Gastroenterology 135:1493-9. 2008
    ..We determined the effects of adalimumab maintenance treatment on the risks of hospitalization and surgery in Crohn's disease (CD)...
  19. doi request reprint Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study
    B G Feagan
    Robarts Research Institute, The University of Western Ontario, London, ON, Canada
    Aliment Pharmacol Ther 31:1276-85. 2010
    ..The effect of certolizumab pegol on employment status and work productivity has not been previously assessed...
  20. doi request reprint Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab
    B G Feagan
    Department of Medicine, Robarts Research Institute, University of Western Ontario, London, Canada
    Aliment Pharmacol Ther 33:541-50. 2011
    ..Certolizumab pegol, administered either every 2 weeks (q2w) or q4w, maintains efficacy in patients previously failing on the anti-TNF agent infliximab (WELCOME study)...
  21. doi request reprint Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol
    B G Feagan
    Robarts Research Institute, University of Western Ontario, 100 Perth Drive, London, ON, Canada
    Aliment Pharmacol Ther 33:1143-51. 2011
    ..Patient-reported outcomes provide unique perspectives on the impact of chronic disease. It is unknown whether a combination of different instruments might improve sensitivity to clinically relevant changes in health status...
  22. doi request reprint Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report
    Brian G Feagan
    Robarts Research Institute, University of Western Ontario, London, Canada
    Inflamm Bowel Dis 18:152-60. 2012
    ..Data from trials of infliximab suggest that high-risk patients and patients with active inflammation (CRP elevation and/or ileocolonic ulcers) may benefit from earlier use of this drug...
  23. ncbi request reprint A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators
    B G Feagan
    London Clinical Trials Research Group, The John P Robarts Research Institute, London, Ont, Canada
    N Engl J Med 342:1627-32. 2000
    ..Better treatments are needed for the maintenance of remission. Although methotrexate is an effective short-term treatment for Crohn's disease, its role in maintaining remissions is not known...
  24. ncbi request reprint Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics
    B G Feagan
    London Clinical Trials Research Group, London, Canada
    Can J Clin Pharmacol 8:188-98. 2001
    ..Infliximab is recommended for the treatment of active Crohn's disease refractory to conventional drugs, and is the treatment of choice for fistulizing Crohn's disease...
  25. doi request reprint Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease
    Brian G Feagan
    Department of Medicine and Biostatistics, Robarts Research Institute, University of Western Ontario, 100 Perth Drive, London, Ontario N6A 5K8, Canada
    Am J Gastroenterol 104:1976-83. 2009
    ..Moderate-to-severe Crohn's disease (CD) is associated with important impairment in health-related quality of life (HRQOL). The aim of this study was to assess the effects of certolizumab pegol (CZP) maintenance therapy on HRQOL...
  26. ncbi request reprint Methotrexate in inflammatory bowel disease
    Brian G Feagan
    University of Western Ontario, 100 Perth Drive, London, ON N6A 5K8, Canada
    Gastroenterol Clin North Am 33:407-20, xi. 2004
    ..A more productive area for future investigations is to explore the use of these drugs in combination with infliximab and other biologic treatments...
  27. ncbi request reprint Maintenance therapy for inflammatory bowel disease
    Brian G Feagan
    Robarts Research Institute, The University of Western Ontario, London, Ontario, Canada
    Am J Gastroenterol 98:S6-S17. 2003
    ..An initial experience with probiotic bacteria for maintenance of remission in ulcerative colitis seems promising. This article reviews the data from randomized, controlled trials of maintenance therapy in inflammatory bowel disease...
  28. ncbi request reprint Health-related quality of life during natalizumab maintenance therapy for Crohn's disease
    Brian G Feagan
    Robarts Research Institute, University of Western Ontario, London, Canada
    Am J Gastroenterol 102:2737-46. 2007
    ..We evaluated the effects of treatment on health-related quality of life (HRQoL) during a randomized controlled trial of natalizumab maintenance therapy (ENACT-2) using both disease-specific and generic measures...
  29. ncbi request reprint Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
    Brian G Feagan
    Robart s Research Institute, University of Western Ontario, London, Ontario, Canada
    Rev Gastroenterol Disord 2:S9-15. 2002
    ..Alternatively, sulfasalazine is effective in the presence of colonic disease. Clinicians must decide on the basis of the existing evidence whether budesonide or mesalamine is the preferred initial therapy for active Crohn's disease...
  30. ncbi request reprint A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease
    B G Levesque
    Robarts Clinical Trials, Inc, Robarts Research Institute, Western University, London, ON, Canada Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA
    Aliment Pharmacol Ther 39:1126-35. 2014
    ..Patients with Crohn's disease (CD) may experience disease relapse on maintenance infliximab. Anti-drug antibodies likely contribute to loss of response, and serum infliximab levels likely correlate with efficacy...
  31. doi request reprint Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease
    R Khanna
    Robarts Clinical Trials Inc, Robarts Research Institute, Western University, London, ON, Canada
    Aliment Pharmacol Ther 38:447-59. 2013
    ..Tumour necrosis factor (TNF)-antagonists have an established role in the treatment of inflammatory bowel diseases (IBDs), however, subtherapeutic drug levels and the formation of anti-drug antibodies (ADAs) may decrease their efficacy...
  32. ncbi request reprint A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin
    B G Feagan
    University of Western Ontario, Robarts Research Institute, London, Canada
    Pharmacotherapy 21:89S-94S. 2001
    ..However, use of the clinical pathway was associated with a 1.7-day reduction in BDPM and fewer admissions of low-risk patients...
  33. ncbi request reprint A review of activity indices and end points for clinical trials in children with Crohn's disease
    Anne M Griffiths
    Hospital for Sick Children, Toronto, Ontario, Canada
    Inflamm Bowel Dis 11:185-96. 2005
    ....
  34. ncbi request reprint Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial
    A Hillary Steinhart
    Department of Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
    Gastroenterology 123:33-40. 2002
    ..Although antibiotics are frequently used to treat Crohn's disease, this practice is not supported by strong evidence from randomized trials...
  35. doi request reprint A randomized trial of arthroscopic surgery for osteoarthritis of the knee
    Alexandra Kirkley
    Fowler Kennedy Sport Medicine Clinic, University of Western Ontario, London, ON, Canada
    N Engl J Med 359:1097-107. 2008
    ..The efficacy of arthroscopic surgery for the treatment of osteoarthritis of the knee is unknown...
  36. ncbi request reprint Infliximab maintenance therapy for fistulizing Crohn's disease
    Bruce E Sands
    Gastrointestinal Unit, Massachusetts General Hospital, and Harvard Medical School, Boston 02114, USA
    N Engl J Med 350:876-85. 2004
    ..It is not known whether infliximab is an effective maintenance therapy for patients with fistulas...
  37. ncbi request reprint Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease
    Paul Rutgeerts
    Afdeling Gastroenterologie, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
    Gastroenterology 126:402-13. 2004
    ..This analysis of Crohn's disease patients treated with infliximab in ACCENT I compared episodic and scheduled treatment strategies under conditions that simulate clinical practice...
  38. ncbi request reprint A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis
    Geert D'Haens
    University Hospital Gasthuisberg, Leuven, Belgium
    Gastroenterology 132:763-86. 2007
  39. ncbi request reprint Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
    Stephen B Hanauer
    Department of Gastroenterology and Nutrition, University of Chicago Medical Center, Chicago, IL 60637, USA
    Lancet 359:1541-9. 2002
    ..We did a randomised controlled trial to assess the benefit of maintenance infliximab therapy in patients with active Crohn's disease who respond to a single infusion of infliximab...
  40. ncbi request reprint Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial
    William J Sandborn
    Mayo Clinic, 200 First Street Southwest, Rochester, Minnesota 55905, USA
    Gastroenterology 125:380-8. 2003
    ..This study determined the effectiveness of tacrolimus for the treatment of Crohn's disease fistulas...
  41. ncbi request reprint The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn's disease remains uncertain
    William J Sandborn
    Gastroenterology 127:990-3. 2004
  42. ncbi request reprint High-level serum antibodies to bacterial antigens are associated with antibiotic-induced clinical remission in Crohn's disease: a pilot study
    William S Mow
    Inflammatory Bowel Disease Center, Division of Gastroenterology, Cedars Sinai Medical Center and UCLA School of Medicine, Los Angeles, California 90048, USA
    Dig Dis Sci 49:1280-6. 2004
    ..Although not statistically significant, these results support further testing to determine whether predominant serum reactivity to certain bacterial antigens may be a marker for efficacious use of antibiotics...
  43. ncbi request reprint Natalizumab induction and maintenance therapy for Crohn's disease
    William J Sandborn
    Mayo Clinic, Rochester, Minn 55905, USA
    N Engl J Med 353:1912-25. 2005
    ..Natalizumab, a humanized monoclonal antibody against alpha4 integrin, inhibits leukocyte adhesion and migration into inflamed tissue...
  44. ncbi request reprint Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease
    Gary R Lichtenstein
    Division of Gastroenterology, Department of Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 4283, USA
    Am J Gastroenterol 101:1030-8. 2006
    ..Theoretical concern exists that rapid luminal healing in Crohn's disease (CD) with therapies like infliximab increases the risk of intestinal stenosis, stricture, or obstruction (SSOs)...
  45. ncbi request reprint Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry
    Gary R Lichtenstein
    Department of Medicine, Division of Gastroenterology, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 4283, USA
    Clin Gastroenterol Hepatol 4:621-30. 2006
    ..Long-term safety data for infliximab and other therapies in Crohn's disease (CD) are needed...
  46. ncbi request reprint Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials
    William J Sandborn
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 100:1780-7. 2005
    ..To evaluate the efficacy and safety of oral budesonide for maintenance of remission in patients with mild to moderately active Crohn's disease (CD) of the ileum and/or ascending colon...
  47. ncbi request reprint Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis
    Walter Reinisch
    Univ Klinik Innere Medizin IV, AKH Wien, Vienna, Austria, and Division of Gastroenterology, Hospital Leuven, Belgium
    Inflamm Bowel Dis 13:1135-40. 2007
    ..Impairment of health-related quality of life, employment, and productivity has been documented in patients with moderate to severe ulcerative colitis...
  48. ncbi request reprint Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial
    Stephan R Targan
    Inflammatory Bowel Disease Center and Division of Gastroenterology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Gastroenterology 132:1672-83. 2007
    ..A randomized placebo-controlled trial evaluated the efficacy of natalizumab induction therapy in patients with Crohn's disease...
  49. ncbi request reprint Infliximab for induction and maintenance therapy for ulcerative colitis
    Paul Rutgeerts
    University Hospital Gasthuisberg, Leuven, Belgium
    N Engl J Med 353:2462-76. 2005
    ..Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor alpha, is an established treatment for Crohn's disease but not ulcerative colitis...
  50. ncbi request reprint Certolizumab pegol for the treatment of Crohn's disease
    William J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    N Engl J Med 357:228-38. 2007
    ..Certolizumab pegol is a pegylated humanized Fab' fragment that binds tumor necrosis factor alpha...
  51. doi request reprint Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial
    Geert D'Haens
    Imelda Gastrointestinal Clinical Research Centre, Bonheiden, Belgium
    Lancet 371:660-7. 2008
    ..We aimed to compare the effectiveness of early use of combined immunosuppression with conventional management in patients with active Crohn's disease who had not previously received glucocorticoids, antimetabolites, or infliximab...
  52. doi request reprint A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease
    William J Sandborn
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Gastroenterology 135:1130-41. 2008
    ..Interleukin-12 and interleukin-23 are inflammatory cytokines implicated in Crohn's disease pathophysiology. Ustekinumab is a monoclonal antibody against the p40 subunit of interleukin-12/23...
  53. ncbi request reprint AGA technical review on perianal Crohn's disease
    William J Sandborn
    Clinical Practice Committee, AGA National Office, c o Membership Department, 4930 Del Ray Avenue, Bethesda, MD 20814, USA
    Gastroenterology 125:1508-30. 2003
  54. ncbi request reprint Endoscopic scoring system for Crohn's disease: viva the evolution!
    Brian G Feagan
    Gastrointest Endosc 60:590-1. 2004
  55. ncbi request reprint 5-ASA therapy for active Crohn's disease: old friends, old data, and a new conclusion
    Brian G Feagan
    Clin Gastroenterol Hepatol 2:376-8. 2004
  56. ncbi request reprint Mapping from disease-specific measures to utility: an analysis of the relationships between the Inflammatory Bowel Disease Questionnaire and Crohn's Disease Activity Index in Crohn's disease and measures of utility
    Martin J Buxton
    Health Economics Research Group, Brunel University, Uxbridge, Middlesex, UK
    Value Health 10:214-20. 2007
    ....